Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Hitting out strongly against media reports alleging bribery charges favouring Biocon's unit, Kiran Mazumdar-Shaw took to Twitter to not only deny the allegations but also to shut down trolls. Shaw took an aggressive stance to safeguard the integrity of Biocon as she reminded netizens to read and understand before spreading fake news. The founder of Biocon denied all allegations of wrong doing reported in a PTI news copy that had alleged a 4 lakh bribe was given to a drug controller to waive off a critical insulin trial. Citing procedure Kiran Mazumdar Shaw explained that "The product is EU approved n has conducted full trials globally. All that has been sought is an India trial waiver OK? Pls understand facts before jumping to conclusions. CDSCO provides for trial waiver for EU n US approved products."Biocon Biologics - the unit under question has also issued a statement denying all allegations and is cooperating with CBI as all material and filings are available online with minutes of meetings as well. 

Kiran Mazumdar-Shaw hit back on bribe allegations, strongly denies reports

Kiran Mazumdar-Shaw hit back on bribe allegations, trial waiver was procedural

Kiran Mazumdar-Shaw hits back on bribe allegations, trial waiver was procedural

The CBI registered a case of criminal conspiracy and corruption against Reddy, posted at CDSCO headquarters, and Dinesh Dua, Director at Synergy Network India Private Limited, among others

Hitting out strongly against media reports alleging bribery charges favouring Biocon's unit, Kiran Mazumdar-Shaw took to Twitter to not only deny the allegations but also to shut down trolls.&nbsp; Shaw took an aggressive stance to safeguard the integrity of Biocon as she reminded netizens to read and understand before spreading fake news. The founder of Biocon denied all allegations of wrong doing reported in a PTI news copy that had alleged a 4 lakh bribe was given to a drug controller to waive off a critical insulin trial.&nbsp;
Also read/watch| <a title="&nbsp;Bribe allegations on Biocon's injection unit, Joint drugs controller arrested" href="https://www.editorji.com/business-news/bribe-allegations-on-biocon-s-injection-unit-joint-drugs-controller-arrested-1655783902630">&nbsp;Bribe allegations on Biocon's injection unit, Joint drugs controller arrested</a> Citing procedure Kiran Mazumdar Shaw explained that "The product is EU approved n has conducted full trials globally. All that has been sought is an India trial waiver OK? Pls understand facts before jumping to conclusions. CDSCO provides for trial waiver for EU n US approved products." Biocon Biologics - the unit under question has also issued a statement denying all allegations and is cooperating with CBI as all material and filings are available online with minutes of meetings as well.&nbsp;

With rising cases of Covid the drug regulator met with the association group of chemists and asked the stores to ensure the availability of critical drugs for the management of Covid-19 and other essential medicines. ET reports that the government has said there should not be any shortage of products including all types of cough syrups, paracetamol tablets, Vitamin C, zinc tablets, azithromycin and ivermectin. It has specifically asked chemists to maintain buffer stock of these medicines.
India reported 58,097 new Covid-19 cases and 534 deaths in the 24 hours ending 9 am Wednesday. 

Omicron watch: Govt asks Chemists to stock up on essential medicines, keep buffer stock

The National Pharmaceutical Pricing Authority and the Drug Controller General of India held a meeting with chemists regarding the availability of medicines in the current situation.


Govt asks Chemists to stock up on essential medicines

<ul>
<li>Chemists asked to stock up on essential medicines&nbsp;</li>
<li>Govt wants to ensure enough buffer for medicines in stores&nbsp;</li>
<li>Chemists stock&nbsp;&nbsp;paracetamol tablets, Vitamin C, zinc tablets</li>
<li>
India reported 1,17,100 fresh Covid-19 cases in India in Thursday
</li>
</ul>

India reported over 1 lakh new Covid-19 cases in the 24 hours ending 9 am on Friday, this is the highest tally in 9 months.

With rising cases of Covid&nbsp;the drug regulator met with the association group of chemists and asked the stores to ensure the availability of critical drugs for the management of Covid-19 and other essential medicines.&nbsp; Also watch|<a title="&nbsp;'Don't call it mild': WHO's word of caution against Omicron variant" href="https://www.editorji.com/coronavirus/don-t-call-it-mild-who-s-word-of-caution-against-omicron-variant-1641522335682">&nbsp;'Don't call it mild': WHO's word of caution against Omicron variant</a> ET reports that the government has said there should not be any shortage of products including all types of cough syrups, paracetamol tablets, Vitamin C, zinc tablets, azithromycin and ivermectin. It has specifically asked chemists to maintain buffer stock of these medicines.
India reported over 1 lakh new Covid-19 cases in the 24 hours ending 9 am on Friday, this is the highest tally in 9 months.

In a bid to hasten up the vaccination drive in the country, India regulators have given the nod for a second homegrown vaccine ZyCoV-D, manufactured by Gujarat based Zyd

Meet Zycov D: The world’s first DNA Covid-19 vaccine ; everything you need to know about the new vaccine

Meet Zycov&nbsp;D: Is it really safe for kids? What is a DNA&nbsp;vaccine, How is it administered if it's needle free? All your questions answered here.&nbsp;

Meet ZyCoV-D: The world’s first DNA Covid-19 vaccine; everything you need to know about the new vaccine

The shot is &ldquo;the world&rsquo;s first and India&rsquo;s indigenously developed DNA-based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above.&rdquo;

&nbsp;Zydus&nbsp;Cadila's&nbsp;covid&nbsp;vaccine&nbsp;ZyCoV-D is set to be launched in India in October and is deemed for safe for kids above 12. This&nbsp;&nbsp;'third-generation triple dose vaccine' could just be the answer to fill the gap of 100 crore&nbsp;doses required by year-end to vaccinate the vast majority of the adult population. Here is everything you need to know about this non-injecting, DNA&nbsp;vaccine which even children above 12 can take.&nbsp; Meet&nbsp;Cadila&rsquo;s ZyCoV-D
<ul>
<li>It is the world&rsquo;s first DNA vaccine to protect against Covid&nbsp;19. Requires a triple dose for immunity and showcased 67% efficacy in trials. The vaccine is deemed safe for children above the age of 12.&nbsp;</li>
</ul>
What kind of vaccine is it? How is it different than Covishield&nbsp;and Covaxin?
<ul>
<li>Cadila&rsquo;s ZyCoV-D is a plasmid DNA vaccine that introduces a DNA sequence encoding the antigen in the body and not a weakened form of the pathogen like Covaxin.&nbsp;</li>
</ul>
How does a DNA&nbsp;vaccine work?
<ul>
<li>Often referred to as the third-generation vaccines, the dose carries the genetic code of the virus that triggers the build up of immunity in one's body.&nbsp;</li>
<li>Zydus&nbsp;stated that&nbsp;the plasmid DNA platform is &ldquo;ideally suited for dealing with <a href="https://www.editorji.com/covid-19" target="_blank">Covid-19</a> as it can be easily adapted to deal with mutations in the virus, such as those already occurring&rdquo;.</li>
</ul>
Is a&nbsp;DNA&nbsp;vaccine being used anywhere else in the world?
<ul>
<li>No DNA vaccine has been widely used against any disease so&nbsp; far, but they are more stable and easier to store than mRNA shots (tech used by Pfizer &amp; Moderna)</li>
<li>According to the U.S. National Library of Medicine, over 160 different DNA vaccines are currently being tested in human clinical trials in the United States. It is estimated that 62% of these trials are devoted to cancer vaccines and 33% are applied for vaccines against human immunodeficiency virus (HIV).</li>
</ul>
How many doses does one need?
<ul>
<li>Unlike most other Covid-19 vaccines, which require two doses for full immunity, ZyCoV-D is administered in three doses. The vaccine is also needle-free.</li>
<li>The doses will be administered 28 days apart</li>
</ul>
Needle-free vaccine, how does one get the dose?
<ul>
<li>Doses are given using a device that delivers fluid through a spring-powered jet that penetrates the skin, developed by Pharmajet&rsquo;s Tropis.</li>
<li>Zydus Cadila claims this method of delivery is painless and could also reduce side effects from the jab</li>
</ul>
Is it safe? What are the trial results showing?
<ul>
<li>The vaccine has been tested on almost 30,000 participants across Phase I, II and III studies, and is the first vaccine in India to be tested on 12 to 18-year-olds. Around 1,000 participants were enrolled in the adolescent age group, among whom the vaccine was found to be safe and well-tolerated, with similar findings in the adult population</li>
</ul>
&nbsp;

In what would be a game changer for the vaccine drive against Covid&nbsp;19,&nbsp;Cadila Health has applied to DCGI for emergency use authorisation to launch ZyCoV-D vaccine for for COVID-19. Here is why is this vaccine significant-:&nbsp;

Cadila Health says ZyCoV-D effective against #Delta variant and other mutant strains of Covid-19
Cadila&nbsp;also claims&nbsp;ZyCoV-D safe for children in the age group of 12-18 years as per studies
Vaccine could be available as early as August&nbsp;
Cadila&nbsp;plans to manufacture 10 crore&nbsp;doses annually

ZyCoV-D is a plasma DNA based vaccine for Covid 19 studies and&nbsp;Cadila Health has&nbsp;conducted over 50 clinical sites across India

Vaccine Alert: Cadila applies for nod for ZyCoV-D; says vaccine safe for children between 12-18

In a game changer Cadila&nbsp;applies for approval for "children safe" Covid vaccine&nbsp;ZyCoV-D.&nbsp;

ZyCoV-D vaccine safe for children: Cadila Health 

vaccine, children, Cadila Health, ZyCoV-D

ZyCoV-D is world's first&nbsp;first DNA-based vaccine, Cadila&nbsp;Health ready to supply safe for children vaccine as early as August.&nbsp;

In what would be a game changer for the vaccine drive against Covid&nbsp;19,&nbsp;Cadila Health has applied to DCGI for emergency use authorisation to launch ZyCoV-D vaccine for for COVID-19. Here is why is this vaccine is significant-:&nbsp;
<ul>
<li>Cadila Health says ZyCoV-D effective against #Delta variant and other mutant strains of Covid-19</li>
<li>Cadila&nbsp;also claims&nbsp;ZyCoV-D safe for children in the age group of 12-18 years as per studies.&nbsp;</li>
<li>Vaccine could be available as early as August in the market pending approvals</li>
<li>Cadila&nbsp;plans to manufacture 10 crore&nbsp;doses annually</li>
</ul>
ZyCoV-D is a plasma DNA based vaccine for Covid 19 studies and&nbsp;Cadila Health has&nbsp;conducted trials over 50 clinical sites across India.&nbsp;
Also See |<a href="https://www.editorji.com/story/serum-denied-permission-for-covid-vaccine-covovax-trials-on-children-1625109901643" target="_blank"> Serum denied nod for Covovax&nbsp;trials on children</a>

Johnson &amp; Johnson has agreed to a $230 million settlement with New York state that bars the company from promoting opioids and confirmed it has ended distribution of such products within the United States.
New York Attorney General&rsquo;s office said the agreement bans J&amp;J from promoting opioids through any means and prohibits lobbying about such products at the federal, state or local levels.
The Centers for Disease Control and Prevention estimates that opioid overdoses have killed 500,000 Americans between 1999 and 2019. 
Many of those deaths involved prescription painkillers made by drugmakers and prescribed by doctors.&nbsp;
By settling, J&amp;J will avoid going on trial next week, when New York state is scheduled to face other opioid makers and distributors in court.
&nbsp;

Johnson & Johnson agrees to pay $230 mn to settle New York state opioid case

The settlement will remove Johnson &amp; Johnson from a trial in a lawsuit scheduled to begin Tuesday on Long Island.

J&amp;J settles New York opioid&nbsp;case for $230 mn
Agreement bans J&amp;J from promoting opioids through any means
Company says settlement is not an admission of wrongdoing 500,000 Americans died in a decade due to&nbsp;opioid overdoses

The settlement will remove Johnson &amp; Johnson from a trial in a lawsuit scheduled to begin Tuesday on Long Island in New York state.

Johnson &amp; Johnson has agreed to a $230 million settlement with New York state that bars the company from promoting opioids and confirmed it has ended distribution of such products within the United States.
New York Attorney General&rsquo;s office said the agreement bans J&amp;J from promoting opioids through any means and prohibits lobbying about such products at the federal, state or local levels.
The Centers for Disease Control and Prevention estimates that opioid overdoses have killed 500,000 Americans between 1999 and 2019.
Many of those deaths involved prescription painkillers made by drugmakers and prescribed by doctors.&nbsp;
By settling, J&amp;J will avoid going on trial next week, when New York state is scheduled to face other opioid makers and distributors in court.
&nbsp;

Online medical store PharmEasy's parent entity will acquire a 66% stake in Thyrocare Technologies Ltd, one of the largest diagnostics chains in India. PharmEasy will pick up stake in Thyrocare at ₹1,300 per share, valuing the deal at ₹4,546 crore. The transaction is subject to regulatory and other applicable customary approvals. 
The PharmEasy-Thyrocare deal comes at a time when the online pharmacy sector is witnessing a boom. PharmEasy in a statement said, the collaboration is unique and transformative for the Indian healthcare sector, consumers and the entire healthcare ecosystem.
The statement added that the synergies of both, India&rsquo;s largest digital health platform and one of the largest, cost-effective diagnostics solution providers will accelerate the delivery of high-quality diagnostic and OPD services to nearly 800mn Indians.

PharmEasy to acquire 66% stake in Thyrocare for ₹4,500 crore

Online medical store PharmEasy's parent entity will acquire a 66% stake in Thyrocare Technologies Ltd, one of the largest diagnostics chains in India. PharmEasy will pick up stake in Thyrocare at ₹1,300 per share, valuing the deal at ₹4,546 crore. The transaction is subject to regulatory and other applicable customary approvals.
The PharmEasy-Thyrocare deal comes at a time when the online pharmacy sector is witnessing a boom. PharmEasy in a statement said, the collaboration is unique and transformative for the Indian healthcare sector, consumers and the entire healthcare ecosystem.
The statement added that the synergies of both, India&rsquo;s largest digital health platform and one of the largest, cost-effective diagnostics solution providers will accelerate the delivery of high-quality diagnostic and OPD services to nearly 800mn Indians.

Online medical store PharmEasy's parent entity will acquire a 66% stake in Thyrocare Technologies Ltd, one of the largest diagnostics chains in India. PharmEasy will pick up stake in Thyrocare at ₹1,300 per share, valuing the deal at ₹4,546 crore. The transaction is subject to regulatory and other applicable customary approvals.
The PharmEasy-Thyrocare deal comes at a time when the online pharmacy sector is witnessing a boom. PharmEasy in a statement said, the collaboration is unique and transformative for the Indian healthcare sector, consumers and the entire healthcare ecosystem.
The statement added that the synergies of both, India&rsquo;s largest digital health platform and one of the largest, cost-effective diagnostics solution providers will accelerate the delivery of high-quality diagnostic and OPD services to nearly 800mn Indians.

<ul>
<li>PharmEasy parent API Holdings to buy 66% stake</li>
<li>PharmEasy&nbsp;to pay Rs 4,500 cr for acquisition</li>
<li>First incident of startup buying a listed company</li>
</ul>

PharmEasy&nbsp;looking to ride the health sector wave is eyeing to acquire&nbsp;listed diagnostics services provider Thyrocare&nbsp;in a Rs 7,000 cr deal as per reports.&nbsp;
Moneycontrol&nbsp;reports as per sources that the API&nbsp;holding's the parent company of PharmEasy&nbsp;is likely to&nbsp;announce the deal ahead of it's planned $1.2 million&nbsp;IPO. PharmEasy&nbsp;is also in the spotlight as&nbsp;Tiger Global and&nbsp;Facebook co-founder Eduardo Saverin&rsquo;s B Capital has invested $20 million in medical portal. This fund raising PharmEasy is now valued at $1.8 billion, up from $1.5 billion in April, joining India&rsquo;s fast-growing pool of unicorns.&nbsp;

PharmEasy looks to acquire Thyrocare, valuation soars to $1.8 bn

This medical startup is on an overdose of acquisition, with a backing from Tiger Global and Facebook co-founder.&nbsp;

As Covid has created an ecosystem of innovation in India, Mumbai-based online pharmacy, PharmEasy is in advanced talks to acquire diagnostics services provider Thyrocare in a deal worth approximately Rs 7,000-crore Moneycontrol reported. 

&nbsp;
PharmEasy&nbsp;looking to acquire Thyrocare&nbsp;for Rs 7000 cr: reports Thyrocare: Listed diagnostic service provider&nbsp; PharmEasy&nbsp;raising money from Tiger Global, Facebook&nbsp;co-founder PharmEasy&nbsp;raises $20 million valuing it at $1.8 bn

PharmEasy&nbsp;looking to ride the health sector wave is eyeing to acquire&nbsp;listed diagnostics services provider Thyrocare&nbsp;in a Rs 7,000 cr deal as per reports.&nbsp;
Moneycontrol&nbsp;reports as per sources that the API&nbsp;holding's the parent company of PharmEasy&nbsp;is likely to&nbsp;announce the deal ahead of it's planned $1.2 million&nbsp;IPO. PharmEasy&nbsp;is also in the spotlight as&nbsp;Tiger Global and&nbsp;Facebook co-founder Eduardo Saverin&rsquo;s B Capital has invested $20 million in the medical portal. With this round of fund raising PharmEasy is now valued at $1.8 billion, up from $1.5 billion in April, joining India&rsquo;s fast-growing pool of unicorns.&nbsp;

As pharmacies are among the new verticals in the country&rsquo;s e-commerce sector to have grown during the second wave of the pandemic, E-pharmacy startup PharmEasy said Tuesday it has&nbsp;acquired peer Medlife&nbsp;for an undisclosed amount in a deal that skyrockets its position to number one as India's largest medicine delivery platform.&nbsp;
&ldquo;This will make us the largest healthcare delivery platform across the country by a distance -- serving more than two million families every single month,&rdquo; Dhaval Shah, co-founder of Pharmeasy, wrote on Linkedin.As per the deal, Pharmeasy said that Medlife would discontinue its operations and would be merged with its own platform from May 25. Customers and retail partners of Medlife would be brought onto the Pharmeasy platform, the company added.
&nbsp;

PharmEasy buys Medlife to become India's largest medicine delivery platform

As pharmacies are among the new verticals in the country&rsquo;s e-commerce sector to have grown during the second wave of the pandemic, E-pharmacy startup PharmEasy said Tuesday it has&nbsp;acquired peer Medlife&nbsp;for an undisclosed amount in a deal that skyrockets its position to number one as India's largest medicine delivery platform.&nbsp;
&ldquo;This will make us the largest healthcare delivery platform across the country by a distance -- serving more than two million families every single month,&rdquo; Dhaval Shah, co-founder of Pharmeasy, wrote on Linkedin. As per the deal, Pharmeasy said that Medlife would discontinue its operations and would be merged with its own platform from May 25. Customers and retail partners of Medlife would be brought onto the Pharmeasy platform, the company added.
&nbsp;

Pharmeasy buys Medlife, becomes India's largest online pharmacy
E-pharmacy space has seen a sharp rise due to Covid-19 Pharmeasy&nbsp;&amp;&nbsp;Medlife would&nbsp;merge their&nbsp;platform from May 25
Medlife&nbsp;to discontinue&nbsp;operations from May 25

E-pharmacy startup PharmEasy&nbsp;has&nbsp;acquired peer Medlife&nbsp;for an undisclosed amount in a deal that skyrockets its position to number one as India's largest medicine delivery platform.&nbsp;
Dhaval Shah, co-founder of Pharmeasy, wrote on Linkedin&nbsp;that the acquisition&nbsp;will help the firm serve more than two million families each month. As per the deal, Pharmeasy said that Medlife would discontinue its operations and would be merged with its own platform from May 25. Customers and retail partners of Medlife would be brought onto the Pharmeasy platform.
&nbsp;

pharma

Categories